The latest news for pharma industry insiders.
Site QMS-Based Site Monitoring: The New Frontier for Clinical Research Excellence
Moving towards the development of mature quality management systems.
Women Within Health Care Face Financial Disparities and Are More Likely to Experience Burnout
The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.
Election Wargames: Tech and Politics Try Their Hands at Detecting Voting Threats
‘Risk games’ hosted by Lux Capital expose the difficulty of identifying technology-related election threats.
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com offering.
The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.
How are pharma supply chains adapting to new regulations and industry trends? Kenco’s VP of Life Sciences, Tim McClatchy, outlines three key challenges in Pharmaceutical Commerce Magazine. Dive into the details here!
#lifesciences #PharmaceuticalCommerce #supplychain #3pl #Kenco
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.